Close Menu

NEW YORK (360Dx) – Sygnis today reported a sharp increase in its third quarter and nine-month revenues.

For the three months ended Sept. 30, the Heidelberg, Germany-based firm said that revenues reached €2.4 million ($2.8 million), up 446 percent from the year-ago period. Sygnis did not disclose its Q3 2016 revenue figure.

For the nine months ended Sept. 30, the company reported revenues grew to €5.3 million, up from €976,000 from a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.